Elizabeth Allen

Elizabeth Allen

Auto-generated profile, based on publicly available information

Elizabeth Allen

Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2011 in Health Research Policy and Systems
Verified
Journal Article
Open access
PDF file
JRJoanna Reynolds
Joanna Reynolds
JKJames Kizito
James Kizito
NENkoli Ezumah
Nkoli Ezumah
PMPeter Mangesho
Peter Mangesho
EAElizabeth Allen
Elizabeth Allen
CCClare Chandler
Clare Chandler
Increasing demand for qualitative research within global health has emerged alongside increasing demand for demonstration of quality of research, in line with the evidence-based model of medicine. In quantitative health sciences research, in particular clinical trials, there exist clear and widely-recognised guidelines for conducting quality assurance of research. However, no comparable guidelines exist for qualitative research and although there are long-standing debates on what constitutes 'quality' in qualitative research, the concept of 'quality assurance' has not been explored widely. In acknowledgement of this gap, we sought to review discourses around quality assurance of qualitative research, as a first step towards developing guidance.

16 January 2018 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
EAElizabeth N Allen
Elizabeth N Allen
CCClare Ir Chandler
Clare Ir Chandler
NMNyaradzo Mandimika
Nyaradzo Mandimika
CLCordelia Leisegang
Cordelia Leisegang
KBKaren Barnes
Karen Barnes

3 September 2012 in BMC Pregnancy and Childbirth
Verified
Journal Article
Open access
PDF file
UMUshma Mehta
Ushma Mehta
CCChristine Clerk
Christine Clerk
EAElizabeth Allen
Elizabeth Allen
MYMackensie Yore
Mackensie Yore
ESEsperança Sevene
Esperança Sevene
MGMelba Gomes
Melba Gomes
Background: The absence of robust evidence of safety of medicines in pregnancy, particularly those for major diseases provided by public health programmes in developing countries, has resulted in cautious recommendations on their use. We describe a protocol for a Pregnancy Registry adapted to resource-limited settings aimed at providing evidence on the safety of medicines in pregnancy. Methods/Design: Sentinel health facilities are chosen where women come for prenatal care and are likely to come for delivery. Staff capacity is improved to provide better care during the pregnancy, to identify visible birth defects at delivery and refer infants with major anomalies for surgical or clinical evaluation and treatment. Consenting women are enrolled at their first antenatal visit and careful medical, obstetric and drug-exposure histories taken; medical record linkage is encouraged. Enrolled women are followed up prospectively and their histories are updated at each subsequent visit. The enrolled woman is encouraged to deliver at the facility, where she and her baby can be assessed. Discussion: In addition to data pooling into a common WHO database, the WHO Pregnancy Registry has three important features: First is the inclusion of pregnant women coming for antenatal care, enabling comparison of birth outcomes of women who have been exposed to a medicine with those who have not. Second is its applicability to resource-poor settings regardless of drug or disease. Third is improvement of reproductive health care during pregnancies and at delivery. Facility delivery enables better health outcomes, timely evaluation and management of the newborn, and the collection of reliable clinical data. The Registry aims to improve maternal and neonatal care and also provide much needed information on the safety of medicines in pregnancy.

14 November 2013 in BMC Medical Research Methodology
Verified
Journal Article
Open access
PDF file
EAElizabeth N Allen
Elizabeth N Allen
AMAdiel K Mushi
Adiel K Mushi
IMIsolide Sylvester Massawe
Isolide Sylvester Massawe
LVLasse S Vestergaard
Lasse S Vestergaard
MLMartha Lemnge
Martha Lemnge
CCClare Ir Chandler
Clare Ir Chandler
Accurately characterizing a drug’s safety profile is essential. Trial harm and tolerability assessments rely, in part, on participants’ reports of medical histories, adverse events (AEs), and concomitant medications. Optimal methods for questioning participants are unclear, but different methods giving different results can undermine meta-analyses. This study compared methods for eliciting such data and explored reasons for dissimilar participant responses.

26 June 2009 in Malaria Journal
Verified
Journal Article
Open access
PDF file
EAElizabeth N Allen
Elizabeth N Allen
FLFrancesca Little
Francesca Little
TCTunisio Camba
Tunisio Camba
YCYasmin Cassam
Yasmin Cassam
JRJaishree Raman
Jaishree Raman
Karen I BarnesKaren I Barnes
Karen I Barnes
Background: An artemisinin-based combination therapy, artesunate (AS) plus sulphadoxine-pyrimethamine (SP), was compared to SP monotherapy to provide evidence of further treatment options in southern Mozambique. Methods: Between 2003 and 2005, 411 patients over one year and 10 kg with uncomplicated Plasmodium falciparum malaria were randomly allocated SP (25/1.25 mg per kg day 0) or AS/SP (as above plus 4 mg/kg artesunate days 0, 1 and 2). Allocation was concealed, but treatment was open-label except to microscopists. The primary objective was the relative risk of treatment failure, which was assessed using World Health Organization response definitions modified to a 42-day follow-up. Results: Of the 411 subjects enrolled, 359 (87.3%) completed the follow up period (SP n = 175, AS/SP n = 184). A survival analysis including 408 subjects showed that the polymerase chain reaction-adjusted cure rates were 90.4% (95% confidence interval [CI] 84.9%–93.9%) and 98.0% (95% CI 94.8%–99.3%) for SP and AS/SP respectively. Multivariable analysis showed that treatment with AS/SP decreased the relative hazard of treatment failure by 80% compared to SP (hazard ratio [HR] 0.2; 95% CI 0.1–0.6) and age over seven years decreased the relative hazard of failure by 70% (HR 0.3; 95% CI 0.1–0.9), when compared to younger age. However, having a quintuple dhfr/dhps mutation increased the relative hazard of failure compared to fewer mutations (HR 3.2; 95% CI 1.3–7.5) and baseline axillary temperature increased the relative hazard of failure by 50% for each °C increase (HR 1.5; 95% CI 1.1–2.2). Conclusion: While both treatments were efficacious, AS plus SP significantly decreased the relative hazard of treatment failure compared to SP monotherapy Artesunate plus sulphadoxine-pyrimethamine, but not sulphadoxine-pyrimethamine monotherapy, met the current WHO criteria of >95% efficacy for policy implementation. Trial registration: NCT00203736 and NCT00203814

8 September 2022 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Open access
PDF file
EAElizabeth N Allen
Elizabeth N Allen
AWAlison Beriliy Wiyeh
Alison Beriliy Wiyeh
MMMichael McCaul
Michael McCaul
Background The World Health Organization (WHO) recommends parasitological testing of all suspected malaria cases using malaria rapid diagnostic tests (mRDTs) or microscopy prior to treatment. Some governments have extended this responsibility to community health workers (CHWs) to reduce malaria morbidity and mortality through prompt and appropriate treatment. This is an update of a Cochrane Review first published in 2013. Objectives To evaluate community‐based management strategies for treating malaria or fever that incorporate both a definitive diagnosis with an mRDT and appropriate antimalarial treatment. Search methods We searched CENTRAL, MEDLINE, Embase, five other databases, and three trials registers up to 14 September 2021. Selection criteria We included individually randomized trials and cluster‐randomized controlled trials (cRCTs), controlled before‐after studies, and controlled interrupted time series studies in people living in malaria‐endemic areas, comparing programmes that train CHWs and drug shop vendors to perform mRDTs and provide appropriate treatment versus similar programmes that do not use mRDTs, and versus routine health facility care. Data collection and analysis We used standard Cochrane methods. For each dichotomous outcome, we extracted the number of participants with the event and the total number of participants in each group, unless studies presented results at a population level only. Primary outcomes were all‐cause mortality, hospitalizations, and number of people receiving an antimalarial within 24 hours. Secondary outcomes were malaria‐specific mortality, severe malaria, outcomes related to antimalarial treatments, antibiotic prescribing to people with a negative microscopy or polymerase chain reaction (PCR) result, parasitaemia, anaemia, and all adverse events. Main results We included eight studies from several African countries, Afghanistan, and Myanmar. Staff included CHWs and drug shop vendors. Community use of malaria rapid diagnostic tests compared to clinical diagnosis Compared to clinical diagnosis, mRDT diagnosis results in reduced prescribing of antimalarials to people who are found to be malaria parasite‐negative by microscopy or PCR testing (71 fewer per 100 people, 95% confidence interval (CI) 79 to 51 fewer; risk ratio (RR) 0.17, 95% CI 0.07 to 0.40; 3 cRCTs, 7877 participants; moderate‐certainty evidence). This reduction may be greater among CHWs compared to drug shop vendors. People diagnosed by mRDT are more likely to receive appropriate treatment; that is, an antimalarial if they are microscopy‐ or PCR‐positive and no antimalarial if they are microscopy‐ or PCR‐negative (RR 3.04, 95% CI 2.46 to 3.74, 3 cRCTs, 9332 participants; high‐certainty evidence). Three studies found that a small percentage of people with a negative mRDT result (as read by the CHW or drug shop vendors at the time of treatment) were nevertheless given an antimalarial: 38/1368 (2.8%), 44/724 (6.1%) and 124/950 (13.1%). Conversely, in two studies, a few mRDT‐positive people did not receive an antimalarial (0.5% and 0.3%), and one small cross‐over study found that 6/57 (10.5%) people classified as non‐malaria in the clinical diagnosis arm received an antimalarial. Use of mRDTs probably increases antibiotic use compared to clinical diagnosis (13 more per 100 people, 95% CI 3 to 29 more; RR 2.02, 95% CI 1.21 to 3.37; 2 cRCTs, 5179 participants; moderate‐certainty evidence). We were unable to demonstrate any effect on mortality. Community use of malaria rapid diagnostic tests compared to health facility care Results were insufficient to reach any conclusion. Authors' conclusions Use of mRDTs by CHWs and drug shop vendors compared to clinical diagnosis reduces prescribing of antimalarials to people without malaria. Deaths were uncommon in both groups. Antibiotic prescribing was higher in those with a negative mRDT than in those with a negative clinical diagnosis.